Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
Primary Purpose
Non Small Cell Lung Cancer
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)
Sponsored by
About this trial
This is an interventional diagnostic trial for Non Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing EBUS TBNA for evaluation of lymphadenopathy, lung nodule or mass
- Patients must have atypical lymph nodes. Atypical lymph nodes are characterized by >10mm in short axis or lymph nodes 5-10mm in short axis with atypical features.
- Age > 18 years.
- Patients must have platelets count > 50,000
- Ability to understand and willingness to sign a written informed consent and HIPAA consent document
- WOCBP must agree not to get pregnant until the day of the procedure
Exclusion Criteria:
- Patients with uncorrectable coagulopathy will be excluded.
- Patients with hemodynamic instability will be excluded
- Patients with refractory hypoxemia will be excluded
- Patients with therapeutic anticoagulant that cannot be held for 2 days before and 1 day after the procedure.
- Patients who are unable to tolerate general anesthesia according to the anesthesiologist
- Pregnant or breast feeding.
Sites / Locations
- Fox Chase Cancer Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Endobronchial ultrasound transbronchial needle aspirate
Arm Description
Outcomes
Primary Outcome Measures
Compare diagnostic yield
Diagnostic yields of 22g and 19g needles will be evaluated by two blinded cytopathologists. Diagnostic yield refers to a specific diagnosis made on the basis of EBUS TBNA samples.
Secondary Outcome Measures
To compare the sample adequacy of 22g and 19g EBUS TBNA
Cytologic/ histologic analysis that determines the amount of sample collected with the two needles by two blinded cytopathologists
To compare the sample quality of 22g and 19 g EBUS TBNA
Sample quality will be examined by two blinded pathologists as to whether the samples contained only tissue or were contaminated with blood
Full Information
NCT ID
NCT03311620
First Posted
October 3, 2017
Last Updated
October 7, 2020
Sponsor
Fox Chase Cancer Center
1. Study Identification
Unique Protocol Identification Number
NCT03311620
Brief Title
Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
Official Title
TH-112: Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
May 15, 2018 (Actual)
Primary Completion Date
June 8, 2020 (Actual)
Study Completion Date
June 8, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fox Chase Cancer Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Needle biopsy samples are routinely collected to evaluate cytomorphology, immunohistochemical markers and for mutational analysis. With regular use of immunotheraputic interventions, needle biospy has become more frequent and requires bigger samples for an increasing battery of tests. There has been no clear consensus on which biopsy needle yields the best biopsy sample. It is unclear if large 19g needle offers better yield than a 22 g needle. Although previous studies comparing 21, 22 and 19g needles have suggested that larger needles yield larger biopsy sizes, conflictng studies have shown that larger biopsies lead to bloodier samples with potentially smaller fragments of tissue, offering no improvement in diagnostic, yield, adequacy or sample size.
This study compares biopsy samples collected using 19g and 22g needles from patients of non small cell lung cancer (NSCLC) scheduled to undergo endobronchial ultrasound (EBUS) and transbroncial needle aspiration (TBNA).
Detailed Description
Primary Objective To compare the diagnostic yield of 22g and 19g EBUS transbronchial needle aspirate (TBNA)
Secondary Objectives
To compare the sample adequacy of 22g and 19g EBUS TBNA
To compare the sample quality of 22g and 19 g EBUS TBNA
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All abnormal lymph nodes able to be visualized by EBUS will be biopsied with sequential passes until a macroscopic specimen can be seen in the sample container. Each needle size will be used to take consecutive passes until the sample is complete and each pass will consist of 15-20 agitations. The needle size to be used first will be chosen by permuted block randomization scheme by the statistician. After all passes are done with the first needle, the alternate size needle will be used to biopsy the same lymph node. Samples will be placed in separate containers of formalin. Any subsequent lymph nodes in the same patient will be biopsied with the alternate sized needle first. Further, any lung nodules or masses that can be adequately visualized by EBUS where biopsy is clinically indicated will be sampled with both 22g and 19g TBNA needles in the same fashion. However, these lesions will be randomized separately from any lymph nodes biopsied during the case.
Masking
None (Open Label)
Masking Description
The needle size to be used first will be chosen by permuted block randomization scheme by the statistician
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Endobronchial ultrasound transbronchial needle aspirate
Arm Type
Other
Intervention Type
Procedure
Intervention Name(s)
Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)
Intervention Description
Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
Primary Outcome Measure Information:
Title
Compare diagnostic yield
Description
Diagnostic yields of 22g and 19g needles will be evaluated by two blinded cytopathologists. Diagnostic yield refers to a specific diagnosis made on the basis of EBUS TBNA samples.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
To compare the sample adequacy of 22g and 19g EBUS TBNA
Description
Cytologic/ histologic analysis that determines the amount of sample collected with the two needles by two blinded cytopathologists
Time Frame
1 year
Title
To compare the sample quality of 22g and 19 g EBUS TBNA
Description
Sample quality will be examined by two blinded pathologists as to whether the samples contained only tissue or were contaminated with blood
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients undergoing EBUS TBNA for evaluation of lymphadenopathy, lung nodule or mass
Patients must have atypical lymph nodes. Atypical lymph nodes are characterized by >10mm in short axis or lymph nodes 5-10mm in short axis with atypical features.
Age > 18 years.
Patients must have platelets count > 50,000
Ability to understand and willingness to sign a written informed consent and HIPAA consent document
WOCBP must agree not to get pregnant until the day of the procedure
Exclusion Criteria:
Patients with uncorrectable coagulopathy will be excluded.
Patients with hemodynamic instability will be excluded
Patients with refractory hypoxemia will be excluded
Patients with therapeutic anticoagulant that cannot be held for 2 days before and 1 day after the procedure.
Patients who are unable to tolerate general anesthesia according to the anesthesiologist
Pregnant or breast feeding.
Facility Information:
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
34896033
Citation
Manley CJ, Kumar R, Gong Y, Huang M, Wei SS, Nagarathinam R, Haber A, Egleston B, Flieder D, Ehya H. Prospective randomized trial to compare the safety, diagnostic yield and utility of 22-gauge and 19-gauge endobronchial ultrasound transbronchial needle aspirates and processing technique by cytology and histopathology. J Am Soc Cytopathol. 2022 Mar-Apr;11(2):114-121. doi: 10.1016/j.jasc.2021.10.003. Epub 2021 Oct 23.
Results Reference
derived
Learn more about this trial
Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
We'll reach out to this number within 24 hrs